phosphoserine has been researched along with GDC-0623 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anderson, DJ; Belvin, M; Chan, J; Chen, H; Friedman, LS; Haling, JR; Hatzivassiliou, G; Heald, R; Hewitt, JF; Hoeflich, KP; Ludlam, MJ; Luoh, SM; Malek, S; Merchant, M; Orr, C; Peck, A; Price, S; Song, K; Ultsch, M; Wiesmann, C; Zak, M | 1 |
1 other study(ies) available for phosphoserine and GDC-0623
Article | Year |
---|---|
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
Topics: Allosteric Regulation; Azetidines; Cell Survival; Clinical Trials as Topic; Crystallography, X-Ray; Enzyme Activation; Feedback, Physiological; Genes, ras; HCT116 Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Neoplasms; Niacinamide; Oncogene Protein p21(ras); Phosphorylation; Phosphoserine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf | 2013 |